Balchem(US:BCPC)2026-02-20 21:26Financial Performance - The total backlog as of December 31, 2025, was $53,365, an increase from $50,415 at the end of 2024, with significant contributions from the Human Nutrition and Health (HNH) segment[25]. - Research and development expenses for the year ended December 31, 2025, were approximately $18,510, up from $16,793 in 2024 and $15,049 in 2023, indicating a focus on new product development and improvements[29]. - Capital expenditures in 2025 were approximately $43,193, with investments aimed at expanding capacity and improving process reliability across key product lines[31]. - Capital expenditures are projected to range from $40,000 to $45,000 for 2026, focusing on energy and water-saving projects and exploring renewable energy opportunities[31]. - A 100 basis point increase in interest rates would result in an increase in annual interest expense of approximately $1,640[162]. - The company has exposure to foreign currency exchange risk with a notional amount of $108,569 related to a cross-currency swap[164]. - The company’s borrowings under a revolving loan are subject to fluctuating interest rates based on the consolidated net leverage ratio[162]. Segment Performance - The Animal Nutrition and Health (ANH) segment's choline chloride is essential for poultry and swine health, with the company emphasizing its proprietary chelation technology for enhanced nutrient absorption[17]. - The Human Nutrition and Health (HNH) segment focuses on differentiated products such as specialty vitamin K2 and methylsulfonylmethane (MSM), which are critical for various health applications[16]. - The Specialty Products segment includes performance gases like ethylene oxide and propylene oxide, with a focus on compliance with safety and environmental standards in distribution[20]. - The European Commission imposed definitive duties on choline chloride imports from China, affecting the competitive landscape for the ANH segment[27]. Employee and Operational Metrics - As of December 31, 2025, the company employed approximately 1,352 full-time employees, with a turnover rate of 8% for salaried employees and 23% for hourly employees[41][47]. - The recordable injury rate for the company was 0.63 in 2025, showing improvement from 1.39 in 2023[43]. - The company has been successful in attracting and retaining skilled employees, with approximately 16% covered by collective-bargaining agreements[41]. Environmental and Compliance Efforts - The company is committed to reducing greenhouse gas emissions and global water use through new technologies and operational efficiencies[49]. - The company’s compliance with environmental regulations has not materially affected its operations or financial condition[39]. - The EPA re-registered EtO for sterilization of medical devices and certain spices, with a phase-out period for minor applications and compliance deadlines ranging from several months to ten years[34]. Market and Economic Conditions - The company experienced inflationary pressures in 2025, impacting raw material costs, but has implemented measures to ensure a sustainable supply chain[22]. - The company continues to enhance its technological capabilities to optimize productivity and performance[41]. - The company holds over 130 patents and 400 registered trademarks, leveraging intellectual property to maintain competitive advantages in its product offerings[23].